These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 27502396

  • 21. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
    Zhou Y, Yu S, Chen D, Li H, Xu P, Yuan C, Jiang L, Huang M.
    Mol Pharm; 2023 Feb 06; 20(2):905-917. PubMed ID: 36463525
    [Abstract] [Full Text] [Related]

  • 22. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M.
    Thromb Haemost; 2005 May 06; 93(5):964-75. PubMed ID: 15886816
    [Abstract] [Full Text] [Related]

  • 23. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
    Kargiotis O, Chetty C, Gogineni V, Gondi CS, Pulukuri SM, Kyritsis AP, Gujrati M, Klopfenstein JD, Dinh DH, Rao JS.
    Int J Oncol; 2008 Nov 06; 33(5):937-47. PubMed ID: 18949356
    [Abstract] [Full Text] [Related]

  • 24. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
    Gupta R, Chetty C, Bhoopathi P, Lakka S, Mohanam S, Rao JS, Dinh DE.
    Int J Oncol; 2011 Mar 06; 38(3):733-44. PubMed ID: 21181094
    [Abstract] [Full Text] [Related]

  • 25. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
    Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS.
    Int J Oncol; 2006 Apr 06; 28(4):831-9. PubMed ID: 16525631
    [Abstract] [Full Text] [Related]

  • 26. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T.
    Scand J Gastroenterol; 2005 Jul 06; 40(7):783-93. PubMed ID: 16109653
    [Abstract] [Full Text] [Related]

  • 27. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
    Dublin E, Hanby A, Patel NK, Liebman R, Barnes D.
    Am J Pathol; 2000 Oct 06; 157(4):1219-27. PubMed ID: 11021826
    [Abstract] [Full Text] [Related]

  • 28. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 29. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T.
    BMC Cell Biol; 2006 Feb 20; 7():8. PubMed ID: 16504015
    [Abstract] [Full Text] [Related]

  • 30. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching.
    Semina E, Rubina K, Sysoeva V, Rysenkova K, Klimovich P, Plekhanova O, Tkachuk V.
    Eur J Cell Biol; 2016 Sep 20; 95(9):295-310. PubMed ID: 27324124
    [Abstract] [Full Text] [Related]

  • 31. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct 20; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 32. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
    Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, Aubele M.
    Oncotarget; 2015 Apr 10; 6(10):8103-14. PubMed ID: 25797271
    [Abstract] [Full Text] [Related]

  • 33. Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-κb, PKC-δ, ERK1/2, and AMPKα.
    Li H, Chen C.
    Integr Cancer Ther; 2018 Jun 10; 17(2):511-523. PubMed ID: 28627240
    [Abstract] [Full Text] [Related]

  • 34. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH, Mazar A, Henkin J, Rabbani SA.
    Cancer Res; 1997 Aug 15; 57(16):3585-93. PubMed ID: 9270032
    [Abstract] [Full Text] [Related]

  • 35. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G.
    Curr Drug Targets; 2011 Nov 15; 12(12):1744-60. PubMed ID: 21707477
    [Abstract] [Full Text] [Related]

  • 36. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
    Zhang J, Sud S, Mizutani K, Gyetko MR, Pienta KJ.
    Neoplasia; 2011 Jan 15; 13(1):23-30. PubMed ID: 21245937
    [Abstract] [Full Text] [Related]

  • 37. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 15; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 38. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.
    Endo-Munoz L, Cai N, Cumming A, Macklin R, Merida de Long L, Topkas E, Mukhopadhyay P, Hill M, Saunders NA.
    PLoS One; 2015 Feb 15; 10(8):e0133592. PubMed ID: 26317203
    [Abstract] [Full Text] [Related]

  • 39. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC, Sait S, Kohga S, Winston J, Martinick M, Saxena R, Lankes H, Markus G, Harvey S, Gibbs JF.
    Ann Surg Oncol; 2007 Nov 15; 14(11):3117-24. PubMed ID: 17701256
    [Abstract] [Full Text] [Related]

  • 40. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
    Saldanha RG, Xu N, Molloy MP, Veal DA, Baker MS.
    J Proteome Res; 2008 Nov 15; 7(11):4792-806. PubMed ID: 18808175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.